Loss of BAP1 Protein Expression Is an Independent Marker of Poor Prognosis in patients with Low Risk Clear Cell Renal Cell Carcinoma

摘要

PurposeThe majority of patients diagnosed with clear cell renal cell carcinoma (ccRCC) have low-risk disease with a <10% chance of ccRCC-specific death. DNA sequencing revealed that mutations in BAP1 occur in 5–15% of ccRCC and are associated with poor outcomes. The vast majority of BAP1 mutations abolish protein expression. We developed a highly sensitive immunohistochemistry (IHC) assay to assess BAP1 expression. Herein, we utilize our IHC assay to test whether BAP1 expression is an independent marker of ccRCC specific survival particularly in patients classified as low-risk.